RecruitingPhase 3

Efficacy and Safety of Tamsulosin for Children with Posterior Urethral Valve.

Egypt50 participantsStarted 2024-11-01

Plain-language summary

To determine whether there is a role for Tamsulosin, A Selective Alpha-1 Adrenergic Blocker, as therapy in children with Posterior Urethral Valve post valve ablation , and whether there are side effects involved.

Who can participate

Age range12 Years

SexMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Exclusion criteria

✕. Patients with other conditions that can potentially affect lower or upper urinary tract functions (e.g. spinal dysraphism, anorectal malformation and prune belly syndrome)
✕. Patients who were treated with urinary diversion as vesicostomy or cutaneous ureterostomy.
✕. Patients who had primary treatment of PUV ablation at other hospitals.
✕. Contraindications to α blocker treatment.
✕. Patients who refuse to participate in the study

What they're measuring

The effect of alpha adrenergic blocker, tamsulosin, on upper urinary tract in children with posterior urethral valves.

Timeframe: 1 year

The safety of alpha adrenergic blocker, tamsulosin, in children with posterior urethral valves.

Timeframe: 1 year

Trial details

NCT IDNCT06737016

SponsorMansoura University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-05

Contact for this trial

Mohamed Hussiny

+201064156383 mohamedhussiny1@yahoo.com

View on ClinicalTrials.gov More Posterior Urethral Valve trials